The National Institute for Health and Care Excellence (NICE) has recommended that apixaban (Eliquis) be made available on the NHS for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.
The recommended dosage of apixaban is 2.5mg twice daily. The initial dose should be taken 12–24 hours after surgery. Treatment should be continued for 32–38 days following hip surgery or for 10–14 days following knee surgery.
NICE rejected the use of roflumilast (Daxas) for the management of severe chronic obstructive pulmonary disease (COPD). The PDE4 inhibitor is recommended only as part of a clinical study for adults with severe COPD associated with chronic bronchitis with a history of frequent exacerbations, as an add-on to bronchodilator treatment.